Optimizing Vitamin D in the Elderly
- Conditions
- Deficiency of Vitamin D3
- Registration Number
- NCT01554241
- Lead Sponsor
- University of California, San Francisco
- Brief Summary
Vitamin D deficiency is highly prevalent in older people in the absence of vitamin D supplementation. The limited data available show marked inter-individual variability in response to vitamin D supplementation in very old, frail elderly with almost 25% remaining vitamin D deficient (25-OH D \< 20 ng/mL) when receiving the currently recommended 800 IU/day vitamin D. This proposal is for exploratory research on the use of a wide range of oral vitamin D3 doses in frail elderly living in controlled living environments.
- Detailed Description
The investigators will determine the dose response relationship of circulating total and unbound 25-OH vitamin D3 to supplemental vitamin D3 at daily doses of 800 (currently recommended for the elderly), 2000, and 4000 IU or 50,000 IU/weekly in a randomized blinded investigation of 16 weeks duration. The investigators will also compare the efficacy of each dosing regimen in achieving 25-OH vitamin D levels \>20 ng/mL (50 nmol/L) and identify covariates that contribute to inter-individual variation in the dose response relationship. In patients with osteoporosis, relationships between unbound vs. total 25-OH on intact parathyroid hormone and a marker of bone resorption (beta-Ctx) will be analyzed. The investigators will also examine responses of inflammatory cytokines.
Note: as of April 8,2014, there will be no further enrollment in the 50,000 IU/weekly dose group
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
- age over 65
- medically stable
- residing in long-term care or assisted living
- hypercalcemia or high risk for hypercalcemia
- active cancer or malignancy other than non-melanoma skin cancer
- severe renal disease (eGFR <30 ml/mkin/M2)
- small bowel resection or intestinal bypass surgery
- hyperparathyroidism
- granulomatous disease
- clinically unstable (changes in medications or diagnoses within a month, hospitalizations, within 6 months)
- allergy to vitamin D
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Total 25-OH Vitamin D3 Level 16 weeks circulating total 25-OH vitamin D concentration
- Secondary Outcome Measures
Name Time Method Free 25-OH Vitamin D3 16 weeks circulating free 25-OH vitamin D3 concentration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of California
🇺🇸San Francisco, California, United States
University of California🇺🇸San Francisco, California, United States
